Virtual Library
Start Your Search
M. Kataoka
Author of
-
+
P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.03-022 - Feasibility of Adjuvant Therapy with S-1 plus Carboplatin Followed by Maintenance Therapy with S-1 for Resected Non-Small-Cell Lung Cancer (ID 470)
09:30 - 09:30 | Author(s): M. Kataoka
- Abstract
Background:
The prognosis of patients with locally-advanced stages (II or IIIA) non-small-cell lung cancer (NSCLC) is unsatisfactory, even after complete resection, and the 5-year survival rate is <50%, indicating the need for further improvements in postoperative survival. This multicenter study (the Setouchi Lung Cancer Group Study 0701) aimed to evaluate the feasibility of novel adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent, long-term maintenance with S-1 in patients with completely-resected stage II–IIIA NSCLC.
Methods:
Figure 1 Patients received four cycles of S-1 (80 mg/m2/day for 2 weeks, followed by 2 weeks’ rest) plus carboplatin (area under the curve 5, day 1) followed by S-1 (80 mg/m2/day for 2 weeks, followed by 1 week’s rest). Patients unable to continue S-1 plus carboplatin because of severe toxicity converted to single-agent S-1 maintenance. The duration of adjuvant chemotherapy was 10 months in both situations. The primary endpoint was feasibility, defined as the proportion of patients who completed four cycles of S-1 plus carboplatin and single-agent S-1 maintenance for 10 months. The treatment-completion rate was determined and treatment was considered feasible if the lower 90% confidence interval (CI) was ≥50%.
Results:
Figure 1 Eighty-nine patients were enrolled, of whom 87 were eligible and assessable. Seventy-eight patients (89.7%) completed four cycles of S-1 plus carboplatin and 55 (63.2%) completed the following S-1 maintenance therapy for a total of 10 months. The treatment-completion rate was 63.2% (90% CI: 54.4–71.2%), indicating feasibility. There were no treatment-related deaths. Grade 3/4 toxicities included neutropenia (11.5%), thrombocytopenia (10.3%), and anorexia (2.3%). The 2-year relapse-free survival rate was 59.8%.
Conclusion:
We concluded that novel adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 was feasible and tolerable in patients with completely-resected NSCLC.
-
+
P3.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 226)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.08-023 - Evaluation of Multiple Time Resection of Lung Metastases from Colorectal Cancer (ID 394)
09:30 - 09:30 | Author(s): M. Kataoka
- Abstract
Background:
Surgical resection of lung metastasis from colorectal cancer is beneficial for improving the prognosis of patients when no other metastatic lesions exist. However, the efficiency of multiple time resection of lung metastases has not yet been established. We investigated the characteristics and prognosis of multi-time lung resection cases in order to identify the appropriate indication for this procedure.
Methods:
Ninety-nine patients underwent resection of lung metastases from colorectal cancer between 1993 and 2013 at our institute. Among these patients, we investigated 26 cases who underwent lung resection more than twice.
Results:
With regard to the initial stage of disease, one case was stage I, 4 were stage II, 15 were stage III, and 6 were stage IV. Twenty-two patients underwent lung resection twice, and 4 patients underwent lung resection three times. The median follow-up time was 85 months (range, 36–215 months). Twelve cases died of colorectal cancer recurrence. Eight cases died due to metastases to multiple organs including the liver, lymph nodes, and lung. Two cases died of multiple lung metastases, one died of liver metastasis, and one died of mediastinal nodal metastasis. The overall survival curve from second lung resection is shown in the figure (Kaplan-Meier curve, log-rank test). The 5-year overall survival rate was 46.2%, and the 5-year disease-free survival rate was 44.1%. Three out of 4 cases who underwent lung resection three times died within a year after the operation. Figure 1
Conclusion:
A second lung resection seems to be feasible, while a third may not. Precise evaluation of metastatic lesions in other organs before operation and systemic therapy for preventing multiple metastases may be important.
